Related Experiment Video

Updated: Apr 3, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Nano-Sized Drug Delivery Systems: Development and Implication in Treatment of Hepatocellular Carcinoma

Khan Farheen Badrealam1, Mohammad Owais

  • 1Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.

Digestive Diseases (Basel, Switzerland)
|September 24, 2015
PubMed

Insights

Nanotechnology offers new hope for liver cancer treatment. Nanoformulations are being developed to improve chemotherapy effectiveness and patient survival rates for hepatocellular carcinoma (HCC).

Area of Science:

  • Oncology
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Hepatocellular carcinoma (HCC) poses a significant global health challenge with limited treatment options for advanced stages.
  • Current chemotherapeutic strategies for HCC have not significantly improved overall patient survival.
  • Advancements in nanotechnology present novel platforms for cancer therapy.

Purpose of the Study:

  • To review nanoformulations for liver cancer treatment currently in clinical and preclinical development.
  • To explore the potential of nanotechnology in revolutionizing chemotherapeutic modalities for HCC.
  • To provide insight into the role of nanotechnology in addressing the unmet needs in liver cancer therapy.

Main Methods:

  • Systematic review of literature on nanoformulations for liver cancer.
  • Analysis of nanoformulation stages in clinical and preclinical development.
  • Evaluation of nanotechnology's impact on chemotherapeutic strategies.

Main Results:

  • Various nanoformulations are under investigation for HCC treatment.
  • Nanotechnology demonstrates potential to enhance drug delivery and efficacy.
  • Emerging nano-based strategies show promise in preclinical and clinical settings.

Conclusions:

  • Nanotechnology holds significant promise for improving liver cancer treatment outcomes.
  • Nanoformulations represent a revolutionary approach to HCC chemotherapy.
  • Further research and development in nanomedicine are crucial for advancing liver cancer therapy.

More Related Videos

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.9K
Manufacture and Drug Delivery Applications of Silk Nanoparticles09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

16.8K

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
110
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
336
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
247
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
219